Industry Data Request

Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts, revenue forecasts and developing a general understanding of the market.

NOTES:
Table 1 (a) – (c)
(1) Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir).
(2) Some ARVs are masked with an X in order to reduce the total number of regimens and focus on the core components observed in AHOD.
(3) Combinations with an X component are further described by whether the X's are from the NRTI class of drugs or Other (NNRTI, Fusion and Entry Inhibitors, Trial drug) or both NRTI and Other.
(4) Combinations marked with a P indicate a Protease Inhibitor is used in the combination.
(5) NRTI sparing is defined as a regimen without a NRTI component class drug.

Table 7 & 8
(1) Patient are assumed to be on Atripla FDC if the individual drug components of Atripla (Truvada + Efavirenz or Tenofovir + Emtricitabine + Efavirenz) are reported for their regimen after 1/1/2010.
(2) Combination antiretroviral therapy (cART) regimens are defined as 3 or more antiretroviral agents initiated after 1/1/1997 and have duration of usage more than 14 days.
(3) A patient's regimen is classified by selecting the combination antiretroviral therapy regimen with the longest duration in each calendar year. To reduce the total number of possible cART combinations and to avoid direct head-to-head comparison of individual agents, the following groupings are used.

Group Label	Antiretroviral Therapy Agents
NRTI	abacavir, combivir, didanosine, lamivudine, stavudine, trizivir, zalcitabine, zidovudine, hydroxyurea, emtricitabine, truvada, kivexa, apricitabine, adefovir, tenofovir, enfuvirtide, IL-2
NNRTI_1	efavirenz, etravirine
NNRTI_2	nevirapine, delavirdine
PI_1	atazanavir, darunavir
PI_2	kaletra, saquinavir
PI_3	amprenavir, indinavir, nelfinavir, ritonavir, tipranavir, fosamprenavir, lopinavir
II	raltegravir
OTHER	maraviroc, trial drug

Table 1(a): Most frequent ARV combinations (3+ ARVs) in 2008. 357 unique ART regimens; and a total of 2,066 regimens recorded among 1,719 patients on combination ART.

Combination ARV	Count	Cumulative Count (%)	Description of X		
			NRTI	Other	NRTI + Other
TRUVADA-NEV	150	7.3			
TRUVADA-EFAV	143	14.2			
KIVEXA-NEV	127	20.3			
TRUVADA-ATAZ-RITON	97	25.0			
ABC-NEV-X	92	29.5	92		
KIVEXA-EFAV	75	33.1			
ATAZ-RITON-TENOF-X	70	36.5	67	2	1
EFAV-TENOF-X	56	39.2	56		
CBV-NEV	53	41.8			
NEV-TENOF-X	49	44.1	49		
KIVEXA-ATAZ-RITON	48	46.5			
TRUVADA-KALETRA	44	48.6			
KALETRA-TENOF-X	40	50.5	37	3	
ABC-EFAV-X	33	52.1	33		
CBV-EFAV	30	53.6			
NEV-X	26	54.8	26		
TRUVADA-RITON	26	56.1			
KIVEXA-ATAZ	25	57.3			
TRIZ	24	58.5			
ABC-ATAZ-RITON-TENOF	23	59.6			
ABC-ATAZ-RITON-X	23	60.7	23		
ABC-KALETRA-X	17	61.5	17		
EFAV-X	17	62.3	17		
ABC-RITON-X	16	63.1	17		
KIVEXA-KALETRA	15	63.8			
RITON-DARUN-RALT-X	15	64.6	6	5	4
RITON-DARUN-TENOF-X	14	65.2	11		3
CBV-KALETRA	13	65.9			
ABC-X	12	66.5			
CBV-ATAZ	12	67.0			
TRUVADA-ATAZ	12	67.6			
KIVEXA-ATAZ-RITON-TENOF	11	68.2			
ABC-ATAZ-X	10	68.6			
ABC-KALETRA-TENOF	10	69.1			
KIVEXA-RITON	10	69.6			
RITON-DARUN-TENOF-RALT-X	10	70.1	7		3
NRTI SPARING	13	0.6	N/A		

Table 1(b): Most frequent ARV combinations (3+ ARVs) in 2009. 348 unique ART regimens; and a total of 1,986 regimens recorded among 1,707 patients on combination ART.

Combination ARV	Count	Cumulative Count (%)	Description of X		
			NRTI	Other	NRTI + Other
TRUVADA-EFAV	176	8.9			
TRUVADA-NEV	164	17.1			
KIVEXA-NEV	126	23.5			
TRUVADA-ATAZ-RITON	101	28.5			
KIVEXA-EFAV	73	32.2			
ATAZ-RITON-TENOF-X	68	35.6	65	2	1
ABC-NEV-X	67	39.0	67		
EFAV-TENOF-X	62	42.1	62		
TRUVADA-KALETRA	55	44.9			
CBV-NEV	45	47.2			
KIVEXA-ATAZ-RITON	42	49.3			
NEV-TENOF-X	42	51.4	42		
KALETRA-TENOF-X	31	53.0	27	3	1
TRUVADA-RALT	29	54.4			
RITON-DARUN-RALT-X	27	55.8	13	8	6
TRUVADA-RITON	25	57.0			
KIVEXA-ATAZ	23	58.2			
CBV-EFAV	22	59.3			
ABC-ATAZ-RITON-X	21	60.4	21		
TRIZ	21	61.4			
ABC-EFAV-X	20	62.4	20		
ABC-ATAZ-RITON-TENOF	18	63.3			
KIVEXA-KALETRA	17	64.2			
RITON-DARUN-TENOF-X	17	65.1	12	1	4
RITON-DARUN-TENOF-RALT-X	17	65.9	10	3	4
TRUVADA-ATAZ	16	66.7			
NEV-X	14	67.4	14		
TENOF-RALT-X	13	68.1	9	1	3
TRUVADA-RITON-DARUN-RALT-X	13	68.7	2	8	3
ABC-KALETRA-X	11	69.3	11		
KIVEXA-ATAZ-RITON-TENOF	10	69.8			
TRUVADA-RITON-DARUN	10	70.3			
TRUVADA-RITON-DARUN-RALT	10	70.8			
NRTI SPARING	26	1.3	N/A		

Table 1(c): Most frequent ARV combinations (3+ ARVs) in 2010. 335 unique ART regimens; and a total of 2,075 regimens recorded among 1,798 patients on combination ART.

Combination ARV	Count	Cumulative Count (%)	Description of X		
			NRTI	Other	NRTI + Other
TRUVADA-NEV	158	7.6			
TRUVADA-EFAV	155	15.1			
ATRIP	143	22.0			
TRUVADA-ATAZ-RITON	106	27.1			
KIVEXA-NEV	104	32.1			
EFAV-TENOF-X	70	35.5	70		
KIVEXA-EFAV	66	38.7			
ABC-NEV-X	64	41.7	64		
ATAZ-RITON-TENOF-X	60	44.6	59	1	
TRUVADA-KALETRA	51	47.1			
CBV-NEV	43	49.2			
TRUVADA-RALT	43	51.2			
NEV-TENOF-X	42	53.3	42		
RITON-DARUN-RALT-X	41	55.2	11	21	9
KIVEXA-ATAZ-RITON	35	56.9			
KALETRA-TENOF-X	29	58.3	25	3	1
TRUVADA-RITON	25	59.5			
KIVEXA-ATAZ	23	60.6			
RITON-DARUN-TENOF-RALT-X	23	61.7	13	2	8
ABC-ATAZ-RITON-X	21	62.7	21		
ABC-EFAV-X	19	63.7	19		
CBV-EFAV	19	64.6			
TRIZ	18	65.4			
TRUVADA-RITON-X	18	66.3		18	
KIVEXA-KALETRA	17	67.1			
RITON-DARUN-TENOF-X	16	67.9	10	1	5
TENOF-RALT-X	16	68.7	13	1	2
ABC-ATAZ-RITON-TENOF	15	69.4			
TRUVADA-ATAZ	15	70.1			
NEV-X	14	70.8	14		
KALETRA-RALT-X	13	71.4	8	3	2
CBV-KALETRA	12	72.0			
TRUVADA-RITON-DARUN-RALT-X	12	72.6	2	9	1
ABC-KALETRA-X	11	73.1	11		
TRUVADA-RALT-X	11	73.6		10	1
TRUVADA-RITON-DARUN	11	74.2			
ATAZ-RITON-RALT-X	10	74.7	8	2	
KIVEXA-ATAZ-RITON-TENOF	10	75.1			
TRUVADA-RITON-DARUN-RALT	10	75.6			
NRTI SPARING	40	1.9	N/A		

Table 2: The proportion of patients treated at one time with 2 or 3+ of the "3rd" agents: nevirapine, efavirenz, etravririne, indinavir, kaletra, atazanavir, darunavir, raltegravir.

Year	% Treated with **2** "3rd" Agents	% Treated with **3 or more** "3rd" Agents
2007	13.8	0.4
2008	17.7	1.0
2009	20.9	1.9
2010	21.8	2.6

Table 3: The proportion of patients treated with more than 1 of the NRTI drugs: combivir, abacavir, kivexa, trivizivir, truvada, atripla.

Year	% Treated with more than **1 NRTI**
2007	0.7
2008	1.0
2009	1.1
2010	1.2

Table 4 (a): CD4 cell count distribution of patients in follow-up over the period 2007-2010. Median CD4 cell count per calendar year was catergorised into the groupings <200, 200-350, 350-500, >500 cells/μL.

CD4 (cells/μL)	2007 N (%)	2008 N (%)	2009 N (%)	2010 N (%)
<200	88 (5)	81 (4)	86 (4)	89 (4)
200-349	249 (14)	230 (13)	227 (12)	220 (11)
350-499	380 (21)	402 (22)	425 (22)	435 (21)
>500	942 (52)	983 (54)	1064 (56)	1127 (54)
Missing	138 (8)	111 (6)	113 (6)	211 (10)
Total	1797	1807	1915	2082

Table 4 (b): On or Off treatment* by CD4 cell count strata for patients in follow-up over the period 2007-2010.

CD4 (cells/μL)	2007 On/Off	2008 On/Off	2009 On/Off	2010 On/Off
<200	85/3	79/2	83/3	88/1
200-349	239/10	223/7	214/13	207/13
350-499	353/27	369/33	403/22	398/37
>500	880/62	920/63	999/65	1047/80
Missing	108/30	93/18	99/14	185/26
Total	1663/132	1684/123	1798/117	1925/157

*If a patient was On and Off treatment within the same year, then the treatment status with the larger duration of time was used.

Table 5 (a): CD4 cell count distribution of patients who enrolled in AHOD after 1/1/2005 and were recorded in follow-up over the period 2007-2010. Median CD4 cell count per calendar year was catergorised into the groupings <200, 200-350, 350-500, >500 cells/µL.

CD4 (cells/µL)	2007 N (%)	2008 N (%)	2009 N (%)	2010 N (%)
<200	13 (6)	10 (3)	30 (5)	41 (5)
200-349	41 (18)	54 (18)	95 (16)	112 (13)
350-499	51 (23)	82 (28)	158 (27)	215 (25)
>500	107 (48)	136 (46)	273 (47)	434 (51)
Missing	10 (5)	14 (5)	22 (4)	50 (6)
Total	222	296	578	852

Table 5 (b): On or Off treatment by CD4 cell count strata for patients who enrolled in AHOD after 1/1/2005 and were recorded in follow-up over the period 2007-2010.

CD4 (cells/µL)	2007 On/Off	2008 On/Off	2009 On/Off	2010 On/Off
<200	12/1	9/1	28/2	40/1
200-349	36/5	51/3	86/9	102/10
350-499	39/12	63/19	141/17	183/32
>500	77/30	103/33	234/39	368/66
Missing	4/6	8/6	15/7	35/15
Total	168/54	234/62	504/74	728/124

*If a patient was On and Off treatment within the same year, then the treatment status with the larger duration of time was used.

Table 6: The number and proportion of treatment naïve patients with a recent viral load measurement. The latest viral load from all measurement within 1/1/2010 – 31/3/2011 was used to catergorise into groups 0-400, 400-10,000, >10,000 copies/ml.

Viral Load	Recent Visit 2010	
(copies/ml)	N	(%)
0-50^	24	15
50-400	16	10
400-10,000	49	31
>10,000	65	41
Missing	3	2

^It is very likely most of these patients are actually on treatment, however due to reporting errors we have not yet received treatment data.

Table 7: The total number of patients that changed regimen from Atripla to another regimen and of those switches, the regimen they switched to. Regimens components have been reclassified as per the definitions present in the table on pg1. Atripla was made available on the PBS from 1/1/2010. Data based on all treatment changes from 1/1/2010-31/3/2011.

Combination	Number of Patients
Total	**30**
NNRTI_2/NRTI	6
II/NRTI/PI_1/PI_3	4
NNRTI_1/NRTI	4
NRTI/PI_1/PI_3	3
II/NRTI	2
NRTI/NRTI/PI_1/PI_3	2
Other Combinations	9

Table 8: The total number of patients that changed regimen to Atripla from another regimen and of those switches, the regimen they switched from. Regimens components have been reclassified as per the definitions present in the table on pg1. Data based on all treatment changes from 1/1/2010-31/3/2011.

Combination	Number of Patients
Total	**173**
NNRTI_1/NRTI/NRTI	70
NNRTI_1/NRTI	34
NNRTI_2/NRTI	20
NRTI/NRTI/PI_2	7
NRTI/PI_3	5
NNRTI_1/NRTI/NRTI/NRTI	4
NNRTI_2/NRTI/NRTI	4
NRTI/NRTI/PI_1/PI_3	4
NRTI/NRTI/PI_3	4
NRTI/PI_1/PI_3	3
NNRTI_1/NRTI/NRTI/PI_1/PI_3	2
NNRTI_1/NRTI/NRTI/PI_2	2
NNRTI_2/NRTI/PI_3/PI_3	2
NRTI	2
NRTI/NRTI/PI_2/PI_3	2
NRTI/NRTI/PI_3/PI_3	2
NRTI/PI_2	2
Other Combs	4